vs
CENTERSPACE（CSR）与Organogenesis Holdings Inc.（ORGO）财务数据对比。点击上方公司名可切换其他公司
CENTERSPACE的季度营收约是Organogenesis Holdings Inc.的1.7倍（$65.1M vs $37.2M），CENTERSPACE同比增速更快（-3.0% vs -57.1%），过去两年CENTERSPACE的营收复合增速更高（0.0% vs -46.5%）
Centerspace是一家专注于多户住宅物业持有、运营与开发的房地产投资企业，核心业务覆盖美国中西部及落基山西部区域，面向不同租户群体提供经济型及高端住宅选择，重视租户体验与资产长期价值增长。
Organogenesis Holdings Inc.是一家领先的再生医学企业，专注于开发、生产用于伤口护理、外科修复、运动医学和皮肤病领域的先进治疗产品，主要服务美国及部分国际市场的医疗机构与患者，提供经临床验证的医疗解决方案。
CSR vs ORGO — 直观对比
营收规模更大
CSR
是对方的1.7倍
$37.2M
营收增速更快
CSR
高出54.0%
-57.1%
两年增速更快
CSR
近两年复合增速
-46.5%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $37.2M |
| 净利润 | $-15.0M | — |
| 毛利率 | — | 30.8% |
| 营业利润率 | — | -185.1% |
| 净利率 | -23.0% | — |
| 营收同比 | -3.0% | -57.1% |
| 净利润同比 | -258.1% | — |
| 每股收益（稀释后） | $-0.49 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSRORGO
| Q1 26 | $65.1M | $37.2M | ||
| Q4 25 | $66.6M | $225.6M | ||
| Q3 25 | $71.4M | $150.9M | ||
| Q2 25 | $68.5M | $101.0M | ||
| Q1 25 | $67.1M | $86.7M | ||
| Q4 24 | $66.4M | $126.7M | ||
| Q3 24 | $65.0M | $115.2M | ||
| Q2 24 | $65.0M | $130.2M |
净利润CSRORGO
| Q1 26 | $-15.0M | — | ||
| Q4 25 | $-18.4M | $43.7M | ||
| Q3 25 | $53.8M | $21.6M | ||
| Q2 25 | $-14.5M | $-9.4M | ||
| Q1 25 | $-3.7M | $-18.8M | ||
| Q4 24 | $-5.1M | $7.7M | ||
| Q3 24 | $-1.0M | $12.3M | ||
| Q2 24 | $-1.3M | $-17.0M |
毛利率CSRORGO
| Q1 26 | — | 30.8% | ||
| Q4 25 | 96.5% | — | ||
| Q3 25 | 96.5% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.4% | 72.6% | ||
| Q4 24 | 96.5% | 75.5% | ||
| Q3 24 | 96.6% | 76.7% | ||
| Q2 24 | 96.6% | 77.6% |
营业利润率CSRORGO
| Q1 26 | — | -185.1% | ||
| Q4 25 | -15.9% | 28.1% | ||
| Q3 25 | — | 13.7% | ||
| Q2 25 | -9.9% | -12.5% | ||
| Q1 25 | 7.1% | -30.9% | ||
| Q4 24 | 4.3% | 8.1% | ||
| Q3 24 | 9.8% | 5.4% | ||
| Q2 24 | 11.1% | -10.7% |
净利率CSRORGO
| Q1 26 | -23.0% | — | ||
| Q4 25 | -27.7% | 19.4% | ||
| Q3 25 | 75.3% | 14.3% | ||
| Q2 25 | -21.2% | -9.3% | ||
| Q1 25 | -5.6% | -21.7% | ||
| Q4 24 | -7.6% | 6.1% | ||
| Q3 24 | -1.6% | 10.7% | ||
| Q2 24 | -2.0% | -13.1% |
每股收益（稀释后）CSRORGO
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-1.08 | $0.31 | ||
| Q3 25 | $3.19 | $0.11 | ||
| Q2 25 | $-0.87 | $-0.10 | ||
| Q1 25 | $-0.22 | $-0.17 | ||
| Q4 24 | $-0.31 | $0.05 | ||
| Q3 24 | $-0.40 | $0.09 | ||
| Q2 24 | $-0.19 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.6M | $91.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $695.0M | — |
| 总资产 | $1.9B | $520.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSRORGO
| Q1 26 | $7.6M | $91.4M | ||
| Q4 25 | $12.8M | $93.7M | ||
| Q3 25 | $12.9M | $63.7M | ||
| Q2 25 | $12.4M | $73.1M | ||
| Q1 25 | $11.9M | $110.0M | ||
| Q4 24 | $12.0M | $135.6M | ||
| Q3 24 | $14.5M | $94.3M | ||
| Q2 24 | $14.3M | $89.9M |
总债务CSRORGO
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $955.5M | — | ||
| Q4 24 | $955.4M | — | ||
| Q3 24 | $921.3M | $62.3M | ||
| Q2 24 | $931.7M | $63.8M |
股东权益CSRORGO
| Q1 26 | $695.0M | — | ||
| Q4 25 | $719.2M | $300.1M | ||
| Q3 25 | $748.6M | $255.1M | ||
| Q2 25 | $710.1M | $233.2M | ||
| Q1 25 | $636.8M | $242.9M | ||
| Q4 24 | $752.0M | $262.9M | ||
| Q3 24 | $672.5M | $278.5M | ||
| Q2 24 | $680.7M | $263.5M |
总资产CSRORGO
| Q1 26 | $1.9B | $520.0M | ||
| Q4 25 | $1.9B | $598.7M | ||
| Q3 25 | $2.1B | $509.8M | ||
| Q2 25 | $2.0B | $461.1M | ||
| Q1 25 | $1.9B | $467.4M | ||
| Q4 24 | $1.9B | $497.9M | ||
| Q3 24 | $1.9B | $446.3M | ||
| Q2 24 | $1.9B | $443.2M |
负债/权益比CSRORGO
| Q1 26 | — | — | ||
| Q4 25 | 1.42× | — | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 1.57× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.37× | 0.22× | ||
| Q2 24 | 1.37× | 0.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
